TNF Pharmaceuticals (TNFA) announced a collaboration with Renova Health using AI and machine learning technologies to identify high-risk patient groups for studies of isomyosamine, aimed at preserving muscle mass during GLP-1 treatment. The partnership analyzes data from 30,000 patients to optimize recruitment and accelerate isomyosamine drug development. Renova’s platform identifies patient subsets based on underlying conditions, acute events, and medication profiles.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNFA:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue